Liraglutide (Saxenda) vs Semaglutide (Wegovy)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

Liraglutide (Saxenda)

Marketed by Novo Nordisk

Approved in Obesitypeptide
Reliable signal

NCT00781937 · Phase 3 · completed

The trial randomly assigned 212 participants to liraglutide and 210 to placebo in a double-blind, placebo-controlled design, with objective body-weight outcomes assessed at week 56. All three prespecified primary comparisons favored liraglutide and were statistically significant (each p<0.0001), supporting a strong evidence grade.

Next expected readout: December 2026 · NCT07225816 (registry estimate)

Reported efficacy

Change in BMI SDS (Week 0, Week 56): Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54) (met)

Result source: NCT02918279

Semaglutide (Wegovy)

Marketed by Novo Nordisk

Approved in Obesitypeptide
Reliable signal

NCT03548935 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.

Next expected readout: December 2026 · NCT05173714 (registry estimate)

Reported efficacy

Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)

Result source: NCT03574597

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLiraglutide (Saxenda)Semaglutide (Wegovy)
Body weight, % change-8.0% vs -2.6%−5.4 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
20 other results
  • -6.1% vs -0.1% 3.0 mg · wk 56 · n 194 · Phase 3 · primary NCT00781937
  • -5.9% vs -2% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • -4.6% vs -2% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • -7.7% vs -6.5% wk 12 · n 93 · Phase 3 · primary NCT03374956
  • -6.1% vs -1.9% 3.0 mg · wk 160 · n 1467 · Phase 3 · secondary NCT01272219
  • 0.7% vs 0.3% 3.0 mg · wk 68 · n 349 · Phase 3 · secondary NCT01272219
  • 2.9% vs 0.3% 3.0 mg · wk 68 · n 346 · Phase 3 · secondary NCT01272219
  • -8.4% vs -3.1% 3.0 mg · wk 68 · n 349 · Phase 3 · secondary NCT01272219
  • -6.8% vs -3.1% 3.0 mg · wk 68 · n 347 · Phase 3 · secondary NCT01272219
  • -4.7% vs -2.7% 3.0 mg · wk 68 · n 324 · Phase 3 · secondary NCT01272232
  • -3.6% vs -2.7% 1.8 mg · wk 68 · n 164 · Phase 3 · secondary NCT01272232
  • -5.7% vs -1.4% 3 mg · wk 32 · n 44 · Phase 3 · secondary NCT03480022
  • -0.4% vs 3.3% wk 52 · n 17 · Phase 3 · secondary NCT02527200
  • 6.3% vs 3.3% wk 52 · n 14 · Phase 3 · secondary NCT02527200
  • 2.6% vs 3.3% wk 52 · n 31 · Phase 3 · secondary NCT02527200
  • -1.7% vs -1.2% wk 16 · n 18 · Phase 3 · secondary NCT02527200
  • -1.1% vs -1.2% wk 16 · n 16 · Phase 3 · secondary NCT02527200
  • -1.4% vs -1.2% wk 16 · n 34 · Phase 3 · secondary NCT02527200
  • -3.3% vs 0.2% wk 40 · n 29 · Phase 2 · primary NCT03158805
  • -6.6% vs -1.2% 3.0 mg · wk 40 · n 73 · Phase 4 · secondary NCT03038620
-19.5% vs -3.8%−15.7 vs placebo7.2 mg · wk 72 · n 950NCT05646706
28 other results
  • -14.2% vs -2.5% 2.4 mg · wk 68 · n 253 · Phase 3 · primary NCT05064735
  • -13.4% vs -1.9% 2.4 mg · wk 68 · n 193 · Phase 3 · primary NCT03811574
  • -14.4% vs -2.7% 2.4 mg · wk 52 · n 129 · Phase 3 · primary NCT05040971
  • -13.9% vs -2.5% 2.4 mg · wk 52 · n 246 · Phase 3 · primary NCT04788511
  • -12.2% vs -2.2% 2.4 mg · wk 44 · n 159 · Phase 3 · primary NCT06041217
  • -12.5% vs -3.6% 2.4 mg · wk 44 · n 238 · Phase 3 · primary NCT04251156
  • -9.9% vs -1.9% 1.7 mg · wk 68 · n 98 · Phase 3 · primary NCT03811574
  • -16.4% vs -2.6% wk 44 · n 100 · Phase 3 · primary NCT04998136
  • -16.4% vs -2.7% wk 44 · n 96 · Phase 3 · primary NCT04998136
  • -16.4% vs -6.4% 2.4 mg · wk 68 · n 117 · Phase 3 · primary NCT04074161
  • -9.4% vs -0.9% wk 104 · n 7474 · Phase 3 · secondary NCT03574597
  • -17.7% vs -5.4% 2.4 mg · wk 68 · n 520 · Phase 3 · secondary NCT03548987
  • -7.8% vs -6% 2.4 mg · wk 8 · n 396 · Phase 3 · secondary NCT03611582
  • -14.8% vs 2.3% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -16.4% vs -1.6% 2.4 mg · wk 68 · n 117 · Phase 3 · secondary NCT04074161
  • -15.8% vs -3.3% 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.9% vs -7.2% 2.4 mg · wk 68 · n 388 · Phase 3 · secondary NCT03552757
  • -19.5% vs -16.4% 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -5.5% vs -3.1% 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · primary NCT04969939
  • -13.8% vs -2.3% 0.4 mg · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -16.3% vs -2.3% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -11.2% vs -2.3% 0.3 mg · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.4% vs -2.3% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.6% vs -2.3% 0.2 mg · wk 52 · n 94 · Phase 2 · primary NCT02453711
  • -8.6% vs -2.3% 0.1 mg · wk 52 · n 96 · Phase 2 · primary NCT02453711
  • -6.0% vs -2.3% 0.05 mg · wk 52 · n 92 · Phase 2 · primary NCT02453711
  • -4.5% vs -0.2% wk 12 · n 43 · Phase 1 · secondary NCT04779697
  • -13.6% vs -7.4% 2.4 mg · wk 52 · n 207 · Phase 4 · secondary NCT05579249
Weight loss of 5% or more63.2% vs 27.1%+36.1 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
4 other results
  • 50.5% vs 21.9% 3.0 mg · wk 56 · n 194 · Phase 3 · primary NCT00781937
  • 49.9% vs 13.8% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • 35.6% vs 13.8% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • 76% vs 17% wk 52 · n 58 · Phase 4 · primary NCT03048578
87% vs 29.2%+57.8 vs placebo2.4 mg · wk 68 · n 253NCT05064735
1 other result
  • 72.5% vs 17.7% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
Weight loss of 10% or more33.1% vs 10.6%+22.5 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
3 other results
  • 23.4% vs 4.3% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • 14.4% vs 4.3% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • 26.1% vs 6.3% 3.0 mg · wk 56 · n 194 · Phase 3 · secondary NCT00781937
70.4% vs 9.2%+61.2 vs placebo2.4 mg · wk 68 · n 253NCT05064735
9 other results
  • 61.8% vs 8.1% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • 65.9% vs 9.5% 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • 64.6% vs 10.1% 0.4 mg · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 71.9% vs 10.1% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 57.8% vs 10.1% 0.3 mg · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 58.5% vs 10.1% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 56.0% vs 10.1% 0.2 mg · wk 52 · n 94 · Phase 2 · secondary NCT02453711
  • 36.6% vs 10.1% 0.1 mg · wk 52 · n 96 · Phase 2 · secondary NCT02453711
  • 18.9% vs 10.1% 0.05 mg · wk 52 · n 92 · Phase 2 · secondary NCT02453711
Waist circumference, change (cm)-8.2 vs -3.9−4.2 vs placebo3.0 mg · wk 56 · n 2437NCT01272219
24 other results
  • -6.9 vs -3.4 3.0 mg · wk 160 · n 1472 · Phase 3 · secondary NCT01272219
  • -5.7 vs -3.2 3.0 mg · wk 68 · n 324 · Phase 3 · secondary NCT01272232
  • -4.4 vs -0.9 3.0 mg · wk 56 · n 207 · Phase 3 · secondary NCT00781937
  • -6.1 vs -2.7 3.0 mg · wk 56 · n 412 · Phase 3 · secondary NCT01272232
  • -4.4 vs -3.2 1.8 mg · wk 68 · n 164 · Phase 3 · secondary NCT01272232
  • -4.8 vs -2.7 1.8 mg · wk 56 · n 204 · Phase 3 · secondary NCT01272232
  • 100.9 vs 109.9 3 mg · wk 32 · n 44 · Phase 3 · secondary NCT03480022
  • -3.0 vs -2.1 wk 52 · n 17 · Phase 3 · secondary NCT02527200
  • 0.5 vs -2.1 wk 52 · n 13 · Phase 3 · secondary NCT02527200
  • -1.5 vs -2.1 wk 52 · n 30 · Phase 3 · secondary NCT02527200
  • -2.5 vs -1.9 wk 16 · n 18 · Phase 3 · secondary NCT02527200
  • -0.7 vs -1.9 wk 16 · n 15 · Phase 3 · secondary NCT02527200
  • -1.7 vs -1.9 wk 16 · n 33 · Phase 3 · secondary NCT02527200
  • -7.4 vs -4.6 3.0 mg · wk 40 · n 73 · Phase 4 · secondary NCT03038620
  • -9.8 vs -9.5 3.0 mg · wk 104 · n 47 · Phase 2 · secondary NCT00422058
  • -7.9 vs -6 3.0 mg · wk 20 · n 85 · Phase 2 · secondary NCT00422058
  • -9 vs -9.5 1.8 mg / 3.0 mg · wk 104 · n 38 · Phase 2 · secondary NCT00422058
  • -5.9 vs -6 1.8 mg / 3.0 mg · wk 20 · n 83 · Phase 2 · secondary NCT00422058
  • -10 vs -9.5 placebo / 2.4 mg / 3.0 mg · wk 104 · n 47 · Phase 2 · secondary NCT00422058
  • -10.4 vs -9.5 2.4 mg / 3.0 mg · wk 104 · n 45 · Phase 2 · secondary NCT00422058
  • -4.2 vs -6 placebo / 2.4 mg / 3.0 mg · wk 20 · n 90 · Phase 2 · secondary NCT00422058
  • -7.2 vs -6 2.4 mg / 3.0 mg · wk 20 · n 85 · Phase 2 · secondary NCT00422058
  • -8.6 vs -9.5 1.2 mg / 3.0 mg · wk 104 · n 46 · Phase 2 · secondary NCT00422058
  • -5.8 vs -6 1.2 mg / 3.0 mg · wk 20 · n 93 · Phase 2 · secondary NCT00422058
-7.5 vs -1−6.5 vs placebowk 104 · n 7373NCT03574597
35 other results
  • -14.1 vs -4.4 2.4 mg weekly · wk 68 · n 1210 · Phase 3 · secondary NCT03548935
  • -6.9 vs 3.2 2.4 mg · wk 68 · n 518 · Phase 3 · secondary NCT03548987
  • -15.2 vs -4.3 2.4 mg · wk 104 · n 143 · Phase 3 · secondary NCT03693430
  • -9.7 vs -4.3 2.4 mg · wk 68 · n 387 · Phase 3 · secondary NCT03552757
  • -15.2 vs -6.1 2.4 mg · wk 68 · n 371 · Phase 3 · secondary NCT03611582
  • -18 vs -5.6 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -13.3 vs -5.9 2.4 mg · wk 68 · n 253 · Phase 3 · secondary NCT05064735
  • -12.7 vs -0.5 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -13.6 vs -2 2.4 mg · wk 68 · n 114 · Phase 3 · secondary NCT04074161
  • -11.2 vs -1.8 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -10.2 vs -1.9 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -11.6 vs -2.8 2.4 mg · wk 52 · n 129 · Phase 3 · secondary NCT05040971
  • -12 vs -2.8 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • -14.3 vs -4.5 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.1 vs -2.4 2.4 mg · wk 44 · n 159 · Phase 3 · secondary NCT06041217
  • -11.1 vs -3.8 2.4 mg · wk 44 · n 238 · Phase 3 · secondary NCT04251156
  • -7.8 vs -1.8 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -7.6 vs -1.9 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -12 vs -3 wk 44 · n 100 · Phase 3 · secondary NCT04998136
  • -4.8 vs -2.7 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · secondary NCT04969939
  • -12.3 vs -3.5 0.4 mg · wk 52 · n 82 · Phase 2 · secondary NCT02453711
  • -14.9 vs -3.5 0.4 mg (Fast Escalation) · wk 52 · n 91 · Phase 2 · secondary NCT02453711
  • -10.9 vs -3.5 0.3 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -11.1 vs -3.5 0.3 mg (Fast Escalation) · wk 52 · n 73 · Phase 2 · secondary NCT02453711
  • -11.0 vs -3.5 0.2 mg · wk 52 · n 87 · Phase 2 · secondary NCT02453711
  • -8.8 vs -3.5 0.1 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -6.1 vs -3.5 0.05 mg · wk 52 · n 77 · Phase 2 · secondary NCT02453711
  • -18.2 vs -14.7 30 mg/kg + 1.0 mg · wk 72 · n 42 · Phase 2 · secondary NCT05616013
  • -21.3 vs -14.7 30 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -15.8 vs -13.6 30 mg/kg + 1.0 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -19.0 vs -13.6 30 mg/kg + 2.4 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -15.6 vs -14.7 10 mg/kg + 1.0 mg · wk 72 · n 34 · Phase 2 · secondary NCT05616013
  • -18.1 vs -14.7 10 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -14.6 vs -13.6 10 mg/kg + 1.0 mg · wk 48 · n 41 · Phase 2 · secondary NCT05616013
  • -16.6 vs -13.6 10 mg/kg + 2.4 mg · wk 48 · n 39 · Phase 2 · secondary NCT05616013

Body weight, % change

Liraglutide (Saxenda)
-8.0% vs -2.6%−5.4 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
20 other results
  • -6.1% vs -0.1% 3.0 mg · wk 56 · n 194 · Phase 3 · primary NCT00781937
  • -5.9% vs -2% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • -4.6% vs -2% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • -7.7% vs -6.5% wk 12 · n 93 · Phase 3 · primary NCT03374956
  • -6.1% vs -1.9% 3.0 mg · wk 160 · n 1467 · Phase 3 · secondary NCT01272219
  • 0.7% vs 0.3% 3.0 mg · wk 68 · n 349 · Phase 3 · secondary NCT01272219
  • 2.9% vs 0.3% 3.0 mg · wk 68 · n 346 · Phase 3 · secondary NCT01272219
  • -8.4% vs -3.1% 3.0 mg · wk 68 · n 349 · Phase 3 · secondary NCT01272219
  • -6.8% vs -3.1% 3.0 mg · wk 68 · n 347 · Phase 3 · secondary NCT01272219
  • -4.7% vs -2.7% 3.0 mg · wk 68 · n 324 · Phase 3 · secondary NCT01272232
  • -3.6% vs -2.7% 1.8 mg · wk 68 · n 164 · Phase 3 · secondary NCT01272232
  • -5.7% vs -1.4% 3 mg · wk 32 · n 44 · Phase 3 · secondary NCT03480022
  • -0.4% vs 3.3% wk 52 · n 17 · Phase 3 · secondary NCT02527200
  • 6.3% vs 3.3% wk 52 · n 14 · Phase 3 · secondary NCT02527200
  • 2.6% vs 3.3% wk 52 · n 31 · Phase 3 · secondary NCT02527200
  • -1.7% vs -1.2% wk 16 · n 18 · Phase 3 · secondary NCT02527200
  • -1.1% vs -1.2% wk 16 · n 16 · Phase 3 · secondary NCT02527200
  • -1.4% vs -1.2% wk 16 · n 34 · Phase 3 · secondary NCT02527200
  • -3.3% vs 0.2% wk 40 · n 29 · Phase 2 · primary NCT03158805
  • -6.6% vs -1.2% 3.0 mg · wk 40 · n 73 · Phase 4 · secondary NCT03038620
Semaglutide (Wegovy)
-19.5% vs -3.8%−15.7 vs placebo7.2 mg · wk 72 · n 950NCT05646706
28 other results
  • -14.2% vs -2.5% 2.4 mg · wk 68 · n 253 · Phase 3 · primary NCT05064735
  • -13.4% vs -1.9% 2.4 mg · wk 68 · n 193 · Phase 3 · primary NCT03811574
  • -14.4% vs -2.7% 2.4 mg · wk 52 · n 129 · Phase 3 · primary NCT05040971
  • -13.9% vs -2.5% 2.4 mg · wk 52 · n 246 · Phase 3 · primary NCT04788511
  • -12.2% vs -2.2% 2.4 mg · wk 44 · n 159 · Phase 3 · primary NCT06041217
  • -12.5% vs -3.6% 2.4 mg · wk 44 · n 238 · Phase 3 · primary NCT04251156
  • -9.9% vs -1.9% 1.7 mg · wk 68 · n 98 · Phase 3 · primary NCT03811574
  • -16.4% vs -2.6% wk 44 · n 100 · Phase 3 · primary NCT04998136
  • -16.4% vs -2.7% wk 44 · n 96 · Phase 3 · primary NCT04998136
  • -16.4% vs -6.4% 2.4 mg · wk 68 · n 117 · Phase 3 · primary NCT04074161
  • -9.4% vs -0.9% wk 104 · n 7474 · Phase 3 · secondary NCT03574597
  • -17.7% vs -5.4% 2.4 mg · wk 68 · n 520 · Phase 3 · secondary NCT03548987
  • -7.8% vs -6% 2.4 mg · wk 8 · n 396 · Phase 3 · secondary NCT03611582
  • -14.8% vs 2.3% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -16.4% vs -1.6% 2.4 mg · wk 68 · n 117 · Phase 3 · secondary NCT04074161
  • -15.8% vs -3.3% 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.9% vs -7.2% 2.4 mg · wk 68 · n 388 · Phase 3 · secondary NCT03552757
  • -19.5% vs -16.4% 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -5.5% vs -3.1% 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · primary NCT04969939
  • -13.8% vs -2.3% 0.4 mg · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -16.3% vs -2.3% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -11.2% vs -2.3% 0.3 mg · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.4% vs -2.3% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.6% vs -2.3% 0.2 mg · wk 52 · n 94 · Phase 2 · primary NCT02453711
  • -8.6% vs -2.3% 0.1 mg · wk 52 · n 96 · Phase 2 · primary NCT02453711
  • -6.0% vs -2.3% 0.05 mg · wk 52 · n 92 · Phase 2 · primary NCT02453711
  • -4.5% vs -0.2% wk 12 · n 43 · Phase 1 · secondary NCT04779697
  • -13.6% vs -7.4% 2.4 mg · wk 52 · n 207 · Phase 4 · secondary NCT05579249

Weight loss of 5% or more

Liraglutide (Saxenda)
63.2% vs 27.1%+36.1 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
4 other results
  • 50.5% vs 21.9% 3.0 mg · wk 56 · n 194 · Phase 3 · primary NCT00781937
  • 49.9% vs 13.8% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • 35.6% vs 13.8% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • 76% vs 17% wk 52 · n 58 · Phase 4 · primary NCT03048578
Semaglutide (Wegovy)
87% vs 29.2%+57.8 vs placebo2.4 mg · wk 68 · n 253NCT05064735
1 other result
  • 72.5% vs 17.7% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189

Weight loss of 10% or more

Liraglutide (Saxenda)
33.1% vs 10.6%+22.5 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
3 other results
  • 23.4% vs 4.3% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • 14.4% vs 4.3% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • 26.1% vs 6.3% 3.0 mg · wk 56 · n 194 · Phase 3 · secondary NCT00781937
Semaglutide (Wegovy)
70.4% vs 9.2%+61.2 vs placebo2.4 mg · wk 68 · n 253NCT05064735
9 other results
  • 61.8% vs 8.1% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • 65.9% vs 9.5% 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • 64.6% vs 10.1% 0.4 mg · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 71.9% vs 10.1% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 57.8% vs 10.1% 0.3 mg · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 58.5% vs 10.1% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 56.0% vs 10.1% 0.2 mg · wk 52 · n 94 · Phase 2 · secondary NCT02453711
  • 36.6% vs 10.1% 0.1 mg · wk 52 · n 96 · Phase 2 · secondary NCT02453711
  • 18.9% vs 10.1% 0.05 mg · wk 52 · n 92 · Phase 2 · secondary NCT02453711

Waist circumference, change (cm)

Liraglutide (Saxenda)
-8.2 vs -3.9−4.2 vs placebo3.0 mg · wk 56 · n 2437NCT01272219
24 other results
  • -6.9 vs -3.4 3.0 mg · wk 160 · n 1472 · Phase 3 · secondary NCT01272219
  • -5.7 vs -3.2 3.0 mg · wk 68 · n 324 · Phase 3 · secondary NCT01272232
  • -4.4 vs -0.9 3.0 mg · wk 56 · n 207 · Phase 3 · secondary NCT00781937
  • -6.1 vs -2.7 3.0 mg · wk 56 · n 412 · Phase 3 · secondary NCT01272232
  • -4.4 vs -3.2 1.8 mg · wk 68 · n 164 · Phase 3 · secondary NCT01272232
  • -4.8 vs -2.7 1.8 mg · wk 56 · n 204 · Phase 3 · secondary NCT01272232
  • 100.9 vs 109.9 3 mg · wk 32 · n 44 · Phase 3 · secondary NCT03480022
  • -3.0 vs -2.1 wk 52 · n 17 · Phase 3 · secondary NCT02527200
  • 0.5 vs -2.1 wk 52 · n 13 · Phase 3 · secondary NCT02527200
  • -1.5 vs -2.1 wk 52 · n 30 · Phase 3 · secondary NCT02527200
  • -2.5 vs -1.9 wk 16 · n 18 · Phase 3 · secondary NCT02527200
  • -0.7 vs -1.9 wk 16 · n 15 · Phase 3 · secondary NCT02527200
  • -1.7 vs -1.9 wk 16 · n 33 · Phase 3 · secondary NCT02527200
  • -7.4 vs -4.6 3.0 mg · wk 40 · n 73 · Phase 4 · secondary NCT03038620
  • -9.8 vs -9.5 3.0 mg · wk 104 · n 47 · Phase 2 · secondary NCT00422058
  • -7.9 vs -6 3.0 mg · wk 20 · n 85 · Phase 2 · secondary NCT00422058
  • -9 vs -9.5 1.8 mg / 3.0 mg · wk 104 · n 38 · Phase 2 · secondary NCT00422058
  • -5.9 vs -6 1.8 mg / 3.0 mg · wk 20 · n 83 · Phase 2 · secondary NCT00422058
  • -10 vs -9.5 placebo / 2.4 mg / 3.0 mg · wk 104 · n 47 · Phase 2 · secondary NCT00422058
  • -10.4 vs -9.5 2.4 mg / 3.0 mg · wk 104 · n 45 · Phase 2 · secondary NCT00422058
  • -4.2 vs -6 placebo / 2.4 mg / 3.0 mg · wk 20 · n 90 · Phase 2 · secondary NCT00422058
  • -7.2 vs -6 2.4 mg / 3.0 mg · wk 20 · n 85 · Phase 2 · secondary NCT00422058
  • -8.6 vs -9.5 1.2 mg / 3.0 mg · wk 104 · n 46 · Phase 2 · secondary NCT00422058
  • -5.8 vs -6 1.2 mg / 3.0 mg · wk 20 · n 93 · Phase 2 · secondary NCT00422058
Semaglutide (Wegovy)
-7.5 vs -1−6.5 vs placebowk 104 · n 7373NCT03574597
35 other results
  • -14.1 vs -4.4 2.4 mg weekly · wk 68 · n 1210 · Phase 3 · secondary NCT03548935
  • -6.9 vs 3.2 2.4 mg · wk 68 · n 518 · Phase 3 · secondary NCT03548987
  • -15.2 vs -4.3 2.4 mg · wk 104 · n 143 · Phase 3 · secondary NCT03693430
  • -9.7 vs -4.3 2.4 mg · wk 68 · n 387 · Phase 3 · secondary NCT03552757
  • -15.2 vs -6.1 2.4 mg · wk 68 · n 371 · Phase 3 · secondary NCT03611582
  • -18 vs -5.6 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -13.3 vs -5.9 2.4 mg · wk 68 · n 253 · Phase 3 · secondary NCT05064735
  • -12.7 vs -0.5 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -13.6 vs -2 2.4 mg · wk 68 · n 114 · Phase 3 · secondary NCT04074161
  • -11.2 vs -1.8 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -10.2 vs -1.9 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -11.6 vs -2.8 2.4 mg · wk 52 · n 129 · Phase 3 · secondary NCT05040971
  • -12 vs -2.8 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • -14.3 vs -4.5 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.1 vs -2.4 2.4 mg · wk 44 · n 159 · Phase 3 · secondary NCT06041217
  • -11.1 vs -3.8 2.4 mg · wk 44 · n 238 · Phase 3 · secondary NCT04251156
  • -7.8 vs -1.8 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -7.6 vs -1.9 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -12 vs -3 wk 44 · n 100 · Phase 3 · secondary NCT04998136
  • -4.8 vs -2.7 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · secondary NCT04969939
  • -12.3 vs -3.5 0.4 mg · wk 52 · n 82 · Phase 2 · secondary NCT02453711
  • -14.9 vs -3.5 0.4 mg (Fast Escalation) · wk 52 · n 91 · Phase 2 · secondary NCT02453711
  • -10.9 vs -3.5 0.3 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -11.1 vs -3.5 0.3 mg (Fast Escalation) · wk 52 · n 73 · Phase 2 · secondary NCT02453711
  • -11.0 vs -3.5 0.2 mg · wk 52 · n 87 · Phase 2 · secondary NCT02453711
  • -8.8 vs -3.5 0.1 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -6.1 vs -3.5 0.05 mg · wk 52 · n 77 · Phase 2 · secondary NCT02453711
  • -18.2 vs -14.7 30 mg/kg + 1.0 mg · wk 72 · n 42 · Phase 2 · secondary NCT05616013
  • -21.3 vs -14.7 30 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -15.8 vs -13.6 30 mg/kg + 1.0 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -19.0 vs -13.6 30 mg/kg + 2.4 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -15.6 vs -14.7 10 mg/kg + 1.0 mg · wk 72 · n 34 · Phase 2 · secondary NCT05616013
  • -18.1 vs -14.7 10 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -14.6 vs -13.6 10 mg/kg + 1.0 mg · wk 48 · n 41 · Phase 2 · secondary NCT05616013
  • -16.6 vs -13.6 10 mg/kg + 2.4 mg · wk 48 · n 39 · Phase 2 · secondary NCT05616013
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
25 other shared endpoints and safety

Coverage. Liraglutide (Saxenda): 29 of 29 rows · Semaglutide (Wegovy): 29 of 29 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLiraglutide (Saxenda)
Rows use multiple source trials
Semaglutide (Wegovy)
Rows use multiple source trials
BMI
absolute change · kg
0.8 vs -0.1 placebo kg @ 52wka,b
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
-0.7 vs -0.1 placebo kg @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
-0.6 vs -0.1 placebo kg @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
-6.1 vs -1.3 placebo kg @ 52wk2.4 mgb
NCT03693430 · Phase 3 · registry result, not featured evidence
7 other source trials
-2.37 vs -0.88 placebo kg @ 52wk0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-3.36 vs -0.88 placebo kg @ 52wk0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-4.38 vs -0.88 placebo kg @ 52wk0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-4.4 vs -0.88 placebo kg @ 52wk0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-4.48 vs -0.88 placebo kg @ 52wk0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
-5.4 vs -0.88 placebo kg @ 52wk0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-6.21 vs -0.88 placebo kg @ 52wk0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
BMI Loss 5%
responder rate · % of participants
29.4% (n=17) vs 18.2% (n=11) placebo @ 52wka,c,d
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
32.3% (n=31) vs 18.2% (n=11) placebo @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
35.7% (n=14) vs 18.2% (n=11) placebo @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
75.6% (n=131) vs 22.6% (n=62) placebo @ 68wk2.4 mgc,d
Yes
NCT04102189 · Phase 3 · registry result, not featured evidence
BMI SDS
absolute change · score
-0.25 vs -0.02 placebo score @ 56wk3.0 mge,f,g
NCT02918279 · Phase 3
-1.1 vs -0.1 placebo score @ 68wk2.4 mge,f,g
NCT04102189 · Phase 3 · registry result, not featured evidence
Body Fat
percent change · % of baseline
46% (n=44) vs 47.9% (n=23) placebo @ 32wk3 mgh,i,f,j
NCT03480022 · Phase 3 · registry result, not featured evidence
-37.26% (n=41) vs -18.97% (n=38) semaglutide @ 72wk30 mg/kg + 1.0 mga,h,i,f,j
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
show 7 more doses
-8.71% (n=42) vs -3.06% (n=40) semaglutide @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-45.42% (n=34) vs -18.97% (n=38) semaglutide @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-11.33% (n=39) vs -3.06% (n=40) semaglutide @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-33.58% (n=32) vs -18.97% (n=38) semaglutide @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-7.43% (n=34) vs -3.06% (n=40) semaglutide @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-39.46% (n=38) vs -18.97% (n=38) semaglutide @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-8.29% (n=39) vs -3.06% (n=40) semaglutide @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
CRP Change
absolute change · mg
-2.18 vs -0.64 placebo mg @ 40wk3.0 mgk,e,f,l
NCT03038620 · Phase 4 · registry result, not featured evidence
0.54 vs 0.82 placebo mg @ 52wk0.4 mga,k,e,f,l
NCT02453711 · Phase 2 · registry result, not featured evidence
show 6 more doses
0.44 vs 0.82 placebo mg @ 52wk0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.66 vs 0.82 placebo mg @ 52wk0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
0.58 vs 0.82 placebo mg @ 52wk0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.57 vs 0.82 placebo mg @ 52wk0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
0.65 vs 0.82 placebo mg @ 52wk0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
0.71 vs 0.82 placebo mg @ 52wk0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
DBP
absolute change · mmHg
-1 vs -1 placebo mmHg @ 56wk3.0 mge,f,m
NCT02963935 · Phase 3 · registry result, not featured evidence
-4 vs -1 placebo mmHg @ 104wk2.4 mge,f,m
NCT03693430 · Phase 3 · registry result, not featured evidence
Fasting Insulin
absolute change · pmol/L
-19.6 vs -15.3 Orlistat pmol/L @ 104wk3.0 mga,e,f,n
NCT00422058 · Phase 2 · registry result, not featured evidence
show 4 more doses
18.6 vs -15.3 Orlistat pmol/L @ 104wk1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-2.1 vs -15.3 Orlistat pmol/L @ 104wk2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
0.7 vs -15.3 Orlistat pmol/L @ 104wkplacebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-13.5 vs -15.3 Orlistat pmol/L @ 104wk1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-14.1 vs -8.1 placebo pmol/L @ 48wk1.0 mg + 2.4 mge,f,n
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
Fasting Insulin
absolute change · ratio
2.03 vs 0.79 placebo ratio @ 52wka,c,d
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.78 vs 0.79 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
1.45 vs 0.79 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
0.81 vs 1.03 placebo ratio @ 68wk2.4 mgc,d
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
2 other source trials
0.64 vs 0.99 placebo ratio @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
0.64 vs 0.99 placebo ratio @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose
absolute change · mmol/L
-0.23 vs 0.02 Orlistat mmol/L @ 104wk3.0 mga,o,e,f
NCT00422058 · Phase 2 · registry result, not featured evidence
show 4 more doses
-0.09 vs 0.02 Orlistat mmol/L @ 104wk1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.2 vs 0.02 Orlistat mmol/L @ 104wk2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.22 vs 0.02 Orlistat mmol/L @ 104wkplacebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.09 vs 0.02 Orlistat mmol/L @ 104wk1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.5 vs 0.1 placebo mmol/L @ 104wk2.4 mga,o,e,f
NCT03693430 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.46 vs 0.1 placebo mmol/L @ 104wk*2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -8.3 mg/dL as posted
Free Fatty Acids
absolute change · ratio
1.15 vs 1.45 placebo ratio @ 52wka,c,d
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.01 vs 1.45 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
0.85 vs 1.45 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
0.86 vs 1.08 placebo ratio @ 68wk2.4 mgc,d
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
2 other source trials
1.04 vs 1.28 placebo ratio @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
0.96 vs 1.28 placebo ratio @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
-0.35% (n=47) vs -0.18% (n=45) Orlistat @ 104wk3.0 mga,o,e,f
NCT00422058 · Phase 2 · registry result, not featured evidence
show 4 more doses
-0.3% (n=36) vs -0.18% (n=45) Orlistat @ 104wk1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.25% (n=45) vs -0.18% (n=45) Orlistat @ 104wk2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.32% (n=46) vs -0.18% (n=45) Orlistat @ 104wkplacebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.25% (n=45) vs -0.18% (n=45) Orlistat @ 104wk1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.31% (n=7439) vs 0.01% (n=7351) placebo @ 104wko,e,f
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
1 other source trial
-0.5% (n=141) vs -0.1% (n=122) placebo @ 104wk2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
HDL-C
absolute change · ratio
0.99 vs 1.02 placebo ratio @ 52wka,c,p
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.02 vs 1.02 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
1.06 vs 1.02 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
1.05 vs 1.01 placebo ratio @ 104wkc,p
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
IWQOL-Lite-CT Physical Function
responder rate · % of participants
25.3% (n=198) vs 24.2% (n=198) placebo @ 56wk3.0 mgq,b,f,g
NCT02963922 · Phase 3 · registry result, not featured evidence
1 other source trial
37.3% (n=142) vs 34.3% (n=140) placebo @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
25.5% (n=192) vs 11% (n=100) placebo @ 68wk*2.4 mga,q,b,f,g
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 49 Participants as posted
show 1 more dose
19.4% (n=98) vs 11% (n=100) placebo @ 68wk*1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 19 Participants as posted
LDL-C
absolute change · ratio
1.02 vs 1.12 placebo ratio @ 52wka,c,p
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.01 vs 1.12 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
0.99 vs 1.12 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
0.95 vs 0.97 placebo ratio @ 104wkc,p
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
Lean Mass
percent change · % of baseline
-2.47% (n=73) vs -0.9% (n=55) placebo @ 40wk*3.0 mgk,e,f,r
NCT03038620 · Phase 4 · registry result, not featured evidence · converted to % from 2.47 percent change as posted
-1.38% (n=41) vs -5.09% (n=38) semaglutide @ 72wk30 mg/kg + 1.0 mga,k,e,f,r
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
show 7 more doses
6.79% (n=42) vs 2.8% (n=40) semaglutide @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-3% (n=34) vs -5.09% (n=38) semaglutide @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
10.64% (n=39) vs 2.8% (n=40) semaglutide @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-1.96% (n=32) vs -5.09% (n=38) semaglutide @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
6.52% (n=34) vs 2.8% (n=40) semaglutide @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-2.89% (n=38) vs -5.09% (n=38) semaglutide @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
6.89% (n=39) vs 2.8% (n=40) semaglutide @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
SBP
absolute change · mmHg
-2 vs -1 placebo mmHg @ 56wk3.0 mge,f,m
NCT02963935 · Phase 3 · registry result, not featured evidence
-3.8 vs -0.6 placebo mmHg @ 104wke,f,m
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
1 other source trial
-6 vs -1 placebo mmHg @ 104wk2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
SF-36 Physical Functioning
responder rate · % of participants
28.8% (n=198) vs 26.3% (n=198) placebo @ 56wk3.0 mgq,b,f,g
NCT02963922 · Phase 3 · registry result, not featured evidence
1 other source trial
38.7% (n=142) vs 37.9% (n=140) placebo @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
22.4% (n=192) vs 13% (n=100) placebo @ 68wk*2.4 mga,q,b,f,g
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
show 1 more dose
19.4% (n=98) vs 13% (n=100) placebo @ 68wk*1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 19 Participants as posted
Total Cholesterol
absolute change · ratio
1 vs 1.06 placebo ratio @ 52wka,c,p
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.01 vs 1.06 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
1.01 vs 1.06 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
0.95 vs 0.98 placebo ratio @ 104wkc,p
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
Triglycerides
absolute change · ratio
1.07 vs 0.94 placebo ratio @ 52wka,c,p
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.06 vs 0.94 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
1.04 vs 0.94 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
0.82 vs 0.97 placebo ratio @ 104wkc,p
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
VLDL-C
absolute change · ratio
1.06 vs 0.95 placebo ratio @ 52wka,c,s
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.04 vs 0.95 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
1.03 vs 0.95 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
0.76 vs 1 placebo ratio @ 72wk7.2 mga,c,s
NCT05646706 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.76 vs 1 placebo ratio @ 72wk7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
Waist-Hip
ratio to baseline · ratio
-0.01 vs -0.04 placebo ratio @ 52wka,h,c
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
-0.02 vs -0.04 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
-0.02 vs -0.04 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
-0.02 vs -0.01 placebo ratio @ 52wk0.4 mga,h,c
NCT02453711 · Phase 2 · registry result, not featured evidence
show 6 more doses
-0.03 vs -0.01 placebo ratio @ 52wk0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
-0.03 vs -0.01 placebo ratio @ 52wk0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-0.02 vs -0.01 placebo ratio @ 52wk0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
-0.02 vs -0.01 placebo ratio @ 52wk0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-0.02 vs -0.01 placebo ratio @ 52wk0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-0.01 vs -0.01 placebo ratio @ 52wk0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
Weight
absolute change · kg
-8.2 vs -3.8 Orlistat kg @ 104wk3.0 mga,o,e,f
NCT00422058 · Phase 2 · registry result, not featured evidence
show 4 more doses
-5.6 vs -3.8 Orlistat kg @ 104wk1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-6.4 vs -3.8 Orlistat kg @ 104wk2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-5.4 vs -3.8 Orlistat kg @ 104wkplacebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-4.9 vs -3.8 Orlistat kg @ 104wk1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-16.9 vs -2.1 placebo kg @ 104wk2.4 mgo,e,f
NCT03693430 · Phase 3 · registry result, not featured evidence
Weight
percent change · % of baseline
In-trial observation period
-6% (n=198) vs -1.5% (n=198) placebo @ 56wk3.0 mgb,f,m
In-trial observation period
NCT02963922 · Phase 3 · registry result, not featured evidence
1 other source trial
-7.4% (n=142) vs -4% (n=140) placebo @ 56wk3.0 mg
In-trial observation period
NCT02963935 · Phase 3 · registry result, not featured evidence
-15.9% (n=144) vs -1.9% (n=128) placebo @ 104wk2.4 mgb,f,m
In-trial observation period
NCT03693430 · Phase 3 · registry result, not featured evidence
Weight Loss 10%
event count · % of participants
29.5% (n=44) vs 8.7% (n=23) placebo @ 32wk*3 mgq,i,f,t
NCT03480022 · Phase 3 · registry result, not featured evidence · converted to % from 13 Participants as posted
61.8% (n=144) vs 13.3% (n=128) placebo @ 104wk*2.4 mgq,i,f,t
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 89 Participants as posted
Weight Loss 5%
event count · % of participants
56.8% (n=44) vs 21.7% (n=23) placebo @ 32wk*3 mgq,i,f,j
NCT03480022 · Phase 3 · registry result, not featured evidence · converted to % from 25 Participants as posted
90.7% (n=950) vs 36.8% (n=171) placebo @ 72wk*7.2 mgq,i,f,j
Yes
NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 862 Participants as posted
Dropout rate
25%3.0 mgu
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 38 more results
27.4%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
29.2%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
23.4%3.0 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
22.3%1.8 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
25.6%3.0 mg
NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3
10.4%3.0 mg
NCT02918279 · Phase 3
22.7%3 mg
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
34.8%
NCT03048578 · Phase 4 · registry result, not featured evidence
20.7%3.0 mg
NCT03038620 · Phase 4 · registry result, not featured evidence
10%
NCT02911818 · Phase 4 · registry result, not featured evidence
—
NCT01562678 · Phase 4 · registry result, not featured evidence
0%
NCT03115424 · Phase 3 · registry result, not featured evidence
0%
NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3
20%3 mg
NCT03480022 · Phase 3 · registry result, not featured evidence
15%Part A: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
11.8%Part B: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
16.2%3.0 mg
NCT02963922 · Phase 3 · registry result, not featured evidence
—3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
19.7%3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
31.4%
NCT01784965 · Phase 3 · registry result, not featured evidence
8.8%
NCT04883346 · Phase 2 · registry result, not featured evidence
55.2%
NCT03158805 · Phase 2 · registry result, not featured evidence
11.9%
NCT03523273 · Phase 2 · registry result, not featured evidence
10.5%
NCT02647944 · Phase 2 · registry result, not featured evidence
11.8%3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
17.8%1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
21.5%2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
19.4%placebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
10.5%1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
16.7%420 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
16.7%AMG 598 420 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%210 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
0%AMG 598 210 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%70 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
12.5%AMG 598 70 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
12.5%
NCT03041792 · Phase 1 · registry result, not featured evidence
—2.4 mg weeklyu
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 40 more results
5.1%2.4 mg weekly
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
11%2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
3.2%2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
2.9%
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
16.7%2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
15.3%Behavioral Treatment + Medication
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
—Continued Medication (Semaglutide)
NCT05548647 · Phase 4 · registry result, not featured evidence
14.4%2.4 mg
NCT05579249 · Phase 4 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
0%2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
4.6%7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
0%
NCT04998136 · Phase 3 · registry result, not featured evidence
9.2%2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
7.2%2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
2.7%2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
2%2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
1.5%2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
4.8%2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
2.6%2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
2%2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
2%1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
33.9%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
38.6%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
50%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
37.5%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
12.5%
NCT05302596 · Phase 2 · registry result, not featured evidence
0%2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0%1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
2%0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
2.9%0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
6.8%0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
5.9%0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
8.7%0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
6.9%0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
10.7%0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
10.4%
NCT04779697 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
8.5%3.0 mgu
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 38 more results
9.9%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
9%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
9.2%3.0 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
8.5%1.8 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
11.1%3.0 mg
NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3
—3.0 mg
NCT02918279 · Phase 3
—3 mg
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
1.1%
NCT03048578 · Phase 4 · registry result, not featured evidence
—3.0 mg
NCT03038620 · Phase 4 · registry result, not featured evidence
—
NCT02911818 · Phase 4 · registry result, not featured evidence
—
NCT01562678 · Phase 4 · registry result, not featured evidence
—
NCT03115424 · Phase 3 · registry result, not featured evidence
—
NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3
10.9%3 mg
NCT03480022 · Phase 3 · registry result, not featured evidence
—Part A: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
—Part B: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
7.6%3.0 mg
NCT02963922 · Phase 3 · registry result, not featured evidence
—3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
8.5%3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
22.9%
NCT01784965 · Phase 3 · registry result, not featured evidence
—
NCT04883346 · Phase 2 · registry result, not featured evidence
—
NCT03158805 · Phase 2 · registry result, not featured evidence
—
NCT03523273 · Phase 2 · registry result, not featured evidence
10.5%
NCT02647944 · Phase 2 · registry result, not featured evidence
5.4%3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
5.6%1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
9.7%2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
3.1%placebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
4.2%1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
—420 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
—AMG 598 420 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
—210 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
—AMG 598 210 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
—70 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
—AMG 598 70 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
12.5%
NCT03041792 · Phase 1 · registry result, not featured evidence
—2.4 mg weeklyu
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 40 more results
—2.4 mg weekly
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
5.3%2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
—
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
6.4%2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
—Behavioral Treatment + Medication
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
—Continued Medication (Semaglutide)
NCT05548647 · Phase 4 · registry result, not featured evidence
—2.4 mg
NCT05579249 · Phase 4 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
—7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
—
NCT04998136 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
—1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
10.7%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
1.8%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
14.3%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
5.4%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
—
NCT05302596 · Phase 2 · registry result, not featured evidence
—2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—
NCT04779697 · Phase 1 · registry result, not featured evidence
Serious AEs
4.2%3.0 mgu
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 38 more results
15.1%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
6.2%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
8.8%3.0 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
8.6%1.8 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
3.4%3.0 mg
NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3
2.4%3.0 mg
NCT02918279 · Phase 3
16.5%3 mg
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
4.5%
NCT03048578 · Phase 4 · registry result, not featured evidence
0%3.0 mg
NCT03038620 · Phase 4 · registry result, not featured evidence
0%
NCT02911818 · Phase 4 · registry result, not featured evidence
0%
NCT01562678 · Phase 4 · registry result, not featured evidence
8.3%
NCT03115424 · Phase 3 · registry result, not featured evidence
0%
NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3
0%3 mg
NCT03480022 · Phase 3 · registry result, not featured evidence
5%Part A: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
11.8%Part B: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
8.2%3.0 mg
NCT02963922 · Phase 3 · registry result, not featured evidence
4.2%3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
—3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
22.9%
NCT01784965 · Phase 3 · registry result, not featured evidence
0%
NCT04883346 · Phase 2 · registry result, not featured evidence
0%
NCT03158805 · Phase 2 · registry result, not featured evidence
1.5%
NCT03523273 · Phase 2 · registry result, not featured evidence
0%
NCT02647944 · Phase 2 · registry result, not featured evidence
10.8%3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
11.1%1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
7.5%2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
6.1%placebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
9.5%1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
0%420 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
0%AMG 598 420 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%210 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
0%AMG 598 210 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%70 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
0%AMG 598 70 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%
NCT03041792 · Phase 1 · registry result, not featured evidence
9.8%2.4 mg weeklyu
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 40 more results
—2.4 mg weekly
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
7.7%2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
9.9%2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
33.4%
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
9.1%2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
4.2%Behavioral Treatment + Medication
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
0%Continued Medication (Semaglutide)
NCT05548647 · Phase 4 · registry result, not featured evidence
1.2%2.4 mg
NCT05579249 · Phase 4 · registry result, not featured evidence
8.1%2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
7.3%7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
12.9%
NCT04998136 · Phase 3 · registry result, not featured evidence
10%2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
8.7%2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
13.3%2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
5.6%2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
11.3%2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
7.9%2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
7.9%2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
5%2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
7%1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
10.7%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
12.7%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
12.5%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
14.5%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
0%
NCT05302596 · Phase 2 · registry result, not featured evidence
12.5%2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0%2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0%1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
4.3%1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
12.7%0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
6.8%0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
5.8%0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
5.9%0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
4.9%0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
7.8%0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
12.6%0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
2.1%
NCT04779697 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
3.0 mgu
nausea 47.6% (placebo 17.1%)
constipation 26.9% (placebo 12.4%)
diarrhoea 17.9% (placebo 12.4%)
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 35 more results
3.0 mg
nausea 40.8% (placebo 17%)
nasopharyngitis 26.5% (placebo 27.8%)
diarrhoea 25.5% (placebo 14.2%)
NCT01272219 · Phase 3 · Obesity · phase 3
3.0 mg
nausea 43.7% (placebo 17%)
constipation 21.2% (placebo 11.3%)
diarrhoea 21% (placebo 14.2%)
NCT01272219 · Phase 3 · Obesity · phase 3
3.0 mg
hypoglycaemia 44.3% (placebo 27.8%)
nausea 32.7% (placebo 13.7%)
diarrhoea 25.6% (placebo 12.7%)
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
1.8 mg
hypoglycaemia 40% (placebo 27.8%)
nausea 31.4% (placebo 13.7%)
diarrhoea 17.6% (placebo 12.7%)
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
3.0 mg
nausea 26.7% (placebo 6.7%)
diarrhoea 16.5% (placebo 7.8%)
headache 14.2% (placebo 11.2%)
NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3
3.0 mg
nausea 42.4% (placebo 14.3%)
vomiting 34.4% (placebo 4%)
nasopharyngitis 27.2% (placebo 30.2%)
NCT02918279 · Phase 3
3 mg
nausea 41.9%
gastrointestinal hypomotility 35.8%
diarrhoea 27.7%
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
nausea 23.6% (placebo 7%)
constipation 15.7% (placebo 9.3%)
abdominal pain 9% (placebo 2.3%)
NCT03048578 · Phase 4 · registry result, not featured evidence
3.0 mg
gi related 46.7% (placebo 12.9%)
respiratory tract infection 10.9% (placebo 15.1%)
injection site reaction 7.6% (placebo 8.6%)
NCT03038620 · Phase 4 · registry result, not featured evidence
nausea 36% (placebo 4.3%)
upper respiratory infection 32% (placebo 8.7%)
constipation 30% (placebo 0%)
NCT02911818 · Phase 4 · registry result, not featured evidence
nausea 25% (placebo 25%)
NCT01562678 · Phase 4 · registry result, not featured evidence
nausea 16.7% (placebo 11.1%)
vomiting 16.7% (placebo 11.1%)
hgb < 11.5 g/dl 0% (placebo 0%)
NCT03115424 · Phase 3 · registry result, not featured evidence
during study 24.7% (placebo 25%)
NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3
3 mg
nausea 25.5% (placebo 11.1%)
vomiting 9.1% (placebo 0%)
diarrhea 7.3% (placebo 0%)
NCT03480022 · Phase 3 · registry result, not featured evidence
diarrhoea 50% (placebo 16.7%)
abdominal pain 30% (placebo 25%)
constipation 15% (placebo 0%)
NCT02527200 · Phase 3 · registry result, not featured evidence
diarrhoea 41.2% (placebo 16.7%)
abdominal pain 17.6% (placebo 25%)
abdominal pain upper 17.6% (placebo 0%)
NCT02527200 · Phase 3 · registry result, not featured evidence
3.0 mg
nausea 29.7% (placebo 11.7%)
diarrhoea 23.1% (placebo 15.2%)
nasopharyngitis 21.5% (placebo 18.3%)
NCT02963922 · Phase 3 · registry result, not featured evidence
3.0 mg
nausea 47.9% (placebo 17.9%)
constipation 30.3% (placebo 18.6%)
vomiting 23.2% (placebo 5%)
NCT02963935 · Phase 3 · registry result, not featured evidence
elective back surgery 2.9% (placebo 0%)
family issues 2.9% (placebo 0%)
protocol deviation 2.9% (placebo 0%)
NCT01784965 · Phase 3 · registry result, not featured evidence
dyspepsia 23.5%
constipation 11.8%
fatigue 11.8%
NCT04883346 · Phase 2 · registry result, not featured evidence
nausea 65.5% (placebo 45.2%)
constipation 41.4% (placebo 9.7%)
heartburn 34.5% (placebo 6.5%)
NCT03158805 · Phase 2 · registry result, not featured evidence
nausea 59.7% (placebo 15.9%)
diarrhea 34.3% (placebo 8.7%)
abdominal pain/discomfort 28.4% (placebo 5.8%)
NCT03523273 · Phase 2 · registry result, not featured evidence
nausea 63.2% (placebo 9.5%)
headache 26.3% (placebo 19%)
abdominal pain/discomfort 21.1% (placebo 9.5%)
NCT02647944 · Phase 2 · registry result, not featured evidence
3.0 mg
nausea 50.5%
nasopharyngitis 40.9%
headache 23.7%
NCT00422058 · Phase 2 · registry result, not featured evidence
1.8 mg / 3.0 mg
nasopharyngitis 37.8%
nausea 37.8%
gastroenteritis 22.2%
NCT00422058 · Phase 2 · registry result, not featured evidence
2.4 mg / 3.0 mg
nasopharyngitis 45.2%
nausea 41.9%
headache 24.7%
NCT00422058 · Phase 2 · registry result, not featured evidence
placebo / 2.4 mg / 3.0 mg
nasopharyngitis 41.8%
nausea 29.6%
headache 23.5%
NCT00422058 · Phase 2 · registry result, not featured evidence
1.2 mg / 3.0 mg
nasopharyngitis 38.9%
nausea 36.8%
influenza 25.3%
NCT00422058 · Phase 2 · registry result, not featured evidence
420 mg
abdominal pain 0% (placebo 0%)
arthralgia 0% (placebo 0%)
back pain 0% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence
nausea 50% (placebo 0%)
diarrhoea 33.3% (placebo 0%)
upper respiratory tract infection 33.3% (placebo 16.7%)
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
210 mg
upper respiratory tract infection 50% (placebo 16.7%)
arthralgia 16.7% (placebo 0%)
blood creatine phosphokinase increased 16.7% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence
upper respiratory tract infection 66.7% (placebo 16.7%)
constipation 33.3% (placebo 0%)
early satiety 33.3% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
70 mg
back pain 16.7% (placebo 0%)
constipation 16.7% (placebo 0%)
diarrhoea 16.7% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence
decreased appetite 62.5% (placebo 0%)
lipase increased 37.5% (placebo 0%)
nausea 25% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
nausea 46.9% (placebo 3.6%)
diarrhoea 34.4% (placebo 14.3%)
headache 34.4% (placebo 10.7%)
NCT03041792 · Phase 1 · registry result, not featured evidence
2.4 mg weeklyu
nausea 44.1% (placebo 17.4%)
diarrhoea 31.5% (placebo 15.9%)
vomiting 24.6% (placebo 6.6%)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 35 more results
2.4 mg
diarrhoea 14.4% (placebo 7.1%)
nausea 14% (placebo 4.9%)
constipation 11.6% (placebo 6%)
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
2.4 mg
nausea 33.5% (placebo 9.2%)
diarrhoea 21.3% (placebo 11.9%)
vomiting 21.3% (placebo 2.7%)
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
covid-19 20.3% (placebo 20.3%)
nausea 18.1% (placebo 3.8%)
diarrhoea 10.6% (placebo 4%)
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
2.4 mg
nausea 58.2% (placebo 22.1%)
constipation 36.9% (placebo 24.5%)
diarrhoea 36.1% (placebo 22.1%)
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
nausea 73.6% (placebo 25%)
constipation 52.8% (placebo 16.7%)
diarrhea 37.5% (placebo 22.9%)
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
diarrhea 20% (placebo 22.9%)
constipation 10% (placebo 16.7%)
eructation 10% (placebo 6.3%)
NCT05548647 · Phase 4 · registry result, not featured evidence
2.4 mg
decreased appetite 19.3% (placebo 2.5%)
diarrhoea 18.6% (placebo 7.4%)
nausea 18% (placebo 2.5%)
NCT06041217 · Phase 3 · registry result, not featured evidence
7.2 mg
nausea 43.7% (placebo 13.4%)
diarrhoea 27.3% (placebo 12.9%)
vomiting 24.8% (placebo 7%)
NCT05646706 · Phase 3 · registry result, not featured evidence
nausea 37.6% (placebo 14.3%)
diarrhoea 27.7% (placebo 6.1%)
constipation 21.8% (placebo 16.3%)
NCT04998136 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 21.9% (placebo 8.9%)
covid-19 18.6% (placebo 22.2%)
constipation 11.9% (placebo 5.2%)
NCT05064735 · Phase 3 · registry result, not featured evidence
2.4 mg
covid-19 34.8% (placebo 30.4%)
nausea 29% (placebo 4.3%)
constipation 18.1% (placebo 0%)
NCT05040971 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 17.1% (placebo 2.6%)
covid-19 13.7% (placebo 15.4%)
diarrhoea 9.1% (placebo 3.8%)
NCT04788511 · Phase 3 · registry result, not featured evidence
2.4 mg
diarrhoea 26.1% (placebo 10.3%)
nausea 24.1% (placebo 7.1%)
upper respiratory tract infection 20.5% (placebo 20.6%)
NCT04251156 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 42.1% (placebo 17.9%)
vomiting 36.1% (placebo 10.4%)
diarrhoea 21.8% (placebo 19.4%)
NCT04102189 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 61.1% (placebo 22.4%)
constipation 38.9% (placebo 23.5%)
diarrhoea 27.8% (placebo 25.9%)
NCT04074161 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 53.3% (placebo 21.7%)
diarrhoea 34.9% (placebo 23.7%)
constipation 30.9% (placebo 11.2%)
NCT03693430 · Phase 3 · registry result, not featured evidence
2.4 mg
nasopharyngitis 26.6% (placebo 17.8%)
constipation 26.1% (placebo 3%)
nausea 17.6% (placebo 4%)
NCT03811574 · Phase 3 · registry result, not featured evidence
1.7 mg
nasopharyngitis 24% (placebo 17.8%)
diarrhoea 22% (placebo 5.9%)
constipation 19% (placebo 3%)
NCT03811574 · Phase 3 · registry result, not featured evidence
30 mg/kg + 1.0 mg
muscle spasms 64.3%
acne 55.4%
diarrhoea 44.6%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
30 mg/kg + 2.4 mg
muscle spasms 63.6%
acne 52.7%
diarrhoea 49.1%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
10 mg/kg + 1.0 mg
muscle spasms 57.1%
diarrhoea 48.2%
acne 42.9%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
10 mg/kg + 2.4 mg
muscle spasms 65.5%
nausea 61.8%
diarrhoea 52.7%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
gastrointestinal side effects: constipation 57.1%
gi side effects: nausea 28.6%
gi side effects: vomiting 14.3%
NCT05302596 · Phase 2 · registry result, not featured evidence
2.0 mg + 2.4 mg
decreased appetite 87.5% (placebo 75%)
nausea 87.5% (placebo 12.5%)
vomiting 75% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
2.0 mg + 2.4 mg
nausea 62.5% (placebo 12.5%)
constipation 50% (placebo 0%)
vomiting 37.5% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
1.0 mg + 2.4 mg
decreased appetite 87.5% (placebo 75%)
nausea 50% (placebo 12.5%)
abdominal pain 37.5% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
1.0 mg + 2.4 mg
nausea 44.7% (placebo 12.5%)
vomiting 31.9% (placebo 0%)
constipation 25.5% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0.4 mg
nausea 48% (placebo 17.6%)
diarrhoea 37.3% (placebo 11.8%)
constipation 23.5% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.4 mg (Fast Escalation)
nausea 48.5% (placebo 17.6%)
constipation 28.2% (placebo 4.4%)
diarrhoea 27.2% (placebo 11.8%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.3 mg
nausea 41.7% (placebo 17.6%)
diarrhoea 26.2% (placebo 11.8%)
constipation 17.5% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.3 mg (Fast Escalation)
nausea 53.9% (placebo 17.6%)
diarrhoea 27.5% (placebo 11.8%)
vomiting 20.6% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.2 mg
nausea 43.7% (placebo 17.6%)
diarrhoea 34% (placebo 11.8%)
constipation 25.2% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.1 mg
nausea 41.2% (placebo 17.6%)
diarrhoea 24.5% (placebo 11.8%)
nasopharyngitis 22.5% (placebo 11.8%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.05 mg
nausea 31.1% (placebo 17.6%)
diarrhoea 19.4% (placebo 11.8%)
nasopharyngitis 15.5% (placebo 11.8%)
NCT02453711 · Phase 2 · registry result, not featured evidence
nausea 58.3% (placebo 20.8%)
abdominal pain 31.3% (placebo 20.8%)
diarrhea 29.2% (placebo 10.4%)
NCT04779697 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation context differs: registered conditions differ.
  3. cPopulation context differs: registered conditions differ; age eligibility differs (includes children versus adolescents and adults).
  4. dAssessment timepoints differ: 52 weeks versus 68 weeks.
  5. ePopulation comparability has not been reviewed for both studies.
  6. fTreatment context has not been resolved for both arms.
  7. gAssessment timepoints differ: 56 weeks versus 68 weeks.
  8. hTrial phases differ: Phase 3 versus Phase 2.
  9. iPopulation context differs: eligible sex differs (FEMALE versus ALL).
  10. jAssessment timepoints differ: 32 weeks versus 72 weeks.
  11. kTrial phases differ: Phase 4 versus Phase 2.
  12. lAssessment timepoints differ: 40 weeks versus 52 weeks.
  13. mAssessment timepoints differ: 56 weeks versus 104 weeks.
  14. nAssessment timepoints differ: 104 weeks versus 48 weeks.
  15. oTrial phases differ: Phase 2 versus Phase 3.
  16. pAssessment timepoints differ: 52 weeks versus 104 weeks.
  17. qThe reported result categories differ.
  18. rAssessment timepoints differ: 40 weeks versus 72 weeks.
  19. sAssessment timepoints differ: 52 weeks versus 72 weeks.
  20. tAssessment timepoints differ: 32 weeks versus 104 weeks.
  21. uPopulation comparability has not been reviewed for 30 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Liraglutide (Saxenda)

Weight Loss Maintenance 80.8% (n=194) vs 47.9% (n=188) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Weight Regain 5% 1.9% (n=207) vs 17.5% (n=206) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Weight Regain 10% 0% (n=207) vs 2.9% (n=206) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Weight Loss Maintenance 50% 93.2% (n=207) vs 70.9% (n=206) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Weight Loss Maintenance 75% 87.4% (n=207) vs 54.4% (n=206) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Triglycerides 0.02 vs 0.12 placebo mmol/L @ 56wk3.0 mg
absolute change · mmol/L
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
-0.19 vs -0.01 placebo mmol/L @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
LDL-C 0.24 vs 0.33 placebo mmol/L @ 56wk3.0 mg
absolute change · mmol/L
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
-0.01 vs -0.01 placebo mmol/L @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
Total Cholesterol 0.22 vs 0.33 placebo mmol/L @ 56wk3.0 mg
absolute change · mmol/L
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
-0.01 vs 0 placebo mmol/L @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
Metabolic Syndrome 31.4% (n=194) vs 36.7% (n=188) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
HOMA-B 8.51% (n=190) vs 6.16% (n=181) placebo @ 56wk3.0 mg
percent change · % of baseline
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
HOMA-IR -0.01 vs 0.08 placebo ratio @ 56wk3.0 mg
absolute change · ratio
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 6 more results
1.57 vs 0.8 placebo ratio @ 16wk
NCT02527200 · Phase 3 · registry result, not featured evidence
1.43 vs 0.8 placebo ratio @ 16wk
NCT02527200 · Phase 3 · registry result, not featured evidence
1.51 vs 0.8 placebo ratio @ 16wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
2.26 vs 0.88 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
1.45 vs 0.88 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
1.9 vs 0.88 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
Binge Eating Scale 6.6 vs 8.6 placebo score @ 50wk3.0 mg
absolute change · score
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
6.6 vs 6.9 placebo score @ 57wk3.0 mg
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3

+ 160 further endpoints in the CSV export.

Semaglutide (Wegovy)

Weight Loss 5% 80.2% (n=1306) vs 27.8% (n=655) placebo @ 68wk2.4 mg weekly
event count · % of participants
In-trial observation period · Yes
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 1047 Participants as posted
show 3 more results
66.1% (n=404) vs 26.6% (n=403) placebo @ 68wk*2.4 mg
In-trial observation period · Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 267 Participants as posted
79.4% (n=407) vs 44.1% (n=204) placebo @ 68wk*2.4 mg
In-trial observation period · Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 323 Participants as posted
77.1% (n=144) vs 34.4% (n=128) placebo @ 104wk*2.4 mg
In-trial observation period · Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 111 Participants as posted
Weight Loss 15% 50.5% (n=1212) vs 4.9% (n=577) placebo @ 68wk2.4 mg weekly
event count · % of participants
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 612 Participants as posted
show 13 more results
63.7% (n=520) vs 9.2% (n=250) placebo @ 68wk*2.4 mg
Yes
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 331 Participants as posted
25.8% (n=388) vs 3.2% (n=376) placebo @ 68wk*2.4 mg
Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 100 Participants as posted
55.8% (n=373) vs 13.2% (n=189) placebo @ 68wk*2.4 mg
Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 208 Participants as posted
44.9% (n=207) vs 14.1% (n=177) Other Anti-obesity Medications (AOMs) @ 52wk*2.4 mg
Yes
NCT05579249 · Phase 4 · registry result, not featured evidence · converted to % from 93 Participants as posted
48.1% (n=129) vs 1.5% (n=66) placebo @ 52wk*2.4 mg
Yes
NCT05040971 · Phase 3 · registry result, not featured evidence · converted to % from 62 Participants as posted
34.5% (n=238) vs 6% (n=116) placebo @ 44wk*2.4 mg
Yes
NCT04251156 · Phase 3 · registry result, not featured evidence · converted to % from 82 Participants as posted
55.6% (n=117) vs 6.4% (n=78) placebo @ 68wk*2.4 mg
Yes
NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 65 Participants as posted
52.1% (n=144) vs 7% (n=128) placebo @ 104wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 75 Participants as posted
52.3% (n=149) vs 5.4% (n=129) placebo @ 52wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 78 Participants as posted
40.9% (n=193) vs 3% (n=100) placebo @ 68wk*2.4 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 79 Participants as posted
24.5% (n=98) vs 3% (n=100) placebo @ 68wk*1.7 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
66.5% (n=950) vs 7.6% (n=171) placebo @ 72wk*7.2 mg
Yes
NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 632 Participants as posted
53% (n=100) vs 4.2% (n=48) placebo @ 44wk*
Yes
NCT04998136 · Phase 3 · registry result, not featured evidence · converted to % from 53 Participants as posted
Weight Loss 20% 32% (n=1212) vs 1.7% (n=577) placebo @ 68wk2.4 mg weekly
event count · % of participants
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 388 Participants as posted
show 13 more results
13.1% (n=388) vs 1.6% (n=376) placebo @ 68wk*2.4 mg
Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 51 Participants as posted
35.7% (n=373) vs 3.7% (n=189) placebo @ 68wk*2.4 mg
Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 133 Participants as posted
23.7% (n=207) vs 4.5% (n=177) Other Anti-obesity Medications (AOMs) @ 52wk*2.4 mg
Yes
NCT05579249 · Phase 4 · registry result, not featured evidence · converted to % from 49 Participants as posted
24.8% (n=129) vs 0% (n=66) placebo @ 52wk*2.4 mg
Yes
NCT05040971 · Phase 3 · registry result, not featured evidence · converted to % from 32 Participants as posted
14.3% (n=238) vs 1.7% (n=116) placebo @ 44wk*2.4 mg
Yes
NCT04251156 · Phase 3 · registry result, not featured evidence · converted to % from 34 Participants as posted
38.5% (n=117) vs 2.6% (n=78) placebo @ 68wk*2.4 mg
Yes
NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 45 Participants as posted
36.1% (n=144) vs 2.3% (n=128) placebo @ 104wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 52 Participants as posted
34.9% (n=149) vs 2.3% (n=129) placebo @ 52wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 52 Participants as posted
19.7% (n=193) vs 2% (n=100) placebo @ 68wk*2.4 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 38 Participants as posted
11.2% (n=98) vs 2% (n=100) placebo @ 68wk*1.7 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 11 Participants as posted
47.7% (n=950) vs 2.9% (n=171) placebo @ 72wk*7.2 mg
Yes
NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 453 Participants as posted
47.7% (n=950) vs 33.3% (n=189) Semaglutide @ 72wk*7.2 mg
Yes
NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 453 Participants as posted
30% (n=100) vs 0% (n=48) placebo @ 44wk*
Yes
NCT04998136 · Phase 3 · registry result, not featured evidence · converted to % from 30 Participants as posted
SF-36 Physical Functioning 2.3 vs 0.4 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in physical functioning score (SF-36)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 2 more results
1 vs -1.2 placebo score @ 68wk2.4 mg
Change in physical functioning score (SF-36)
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
2.5 vs 1.7 placebo score @ 68wk2.4 mg
Change in physical functioning score (SF-36)
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 - Role Physical 1.1 vs -0.2 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (role-physical score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Bodily Pain 0.5 vs -1.3 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (bodily pain score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 General Health 2 vs -0.6 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (general health score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Vitality 0.7 vs -1.3 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (vitality score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Social Functioning -0.3 vs -1.4 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (social functioning score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 - Role Emotional -0.9 vs -1.5 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (role-emotional score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Mental Health -0.8 vs -1.7 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (mental health score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Physical Component Summary 2.4 vs 0.2 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (physical component summary)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3

+ 117 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Liraglutide (Saxenda)'s landscape · Semaglutide (Wegovy)'s landscape